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Background: South Africa has the largest prevalence of HIV infection. This epidemic impacts 
adults as well as the pediatric population. The presence of drug-resistant mutations to 
antiretroviral therapies among infants and children is on the rise. Few studies have been 
conducted on this topic.  
Objective: The study aims to determine whether drug resistance testing in the form of genotypic 
testing is cost-effective when deciding whether to switch to a new HIV antiretroviral therapy 
following drug failure.  
Method: An interactive research approach is taken by collecting primary data from experts in this 
field. Secondary sources including guidelines from the World Health Organization and the South 
African Department of Health were also analyzed.  
Results: This study finds that, at the moment, genotypic testing is not cost-effective and should 
not be employed in routine primary care clinics.  
Conclusion: Although not recommended for routine care, genotypic testing is extremely 
beneficial when determining the underlining cause of drug resistance and when tailoring 
individual regimens for patients. A scale-up of the HIV response and a low-cost drug resistance 
test are needed in order to make it cost-effective.  
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 By the end of 2010, there were an estimated 34 million people globally living with 
HIV/AIDS, a 17% increase from 2001. Of this, 3.4 million are children where 91% of the 
infected are living in Sub-Saharan Africa (UNAIDS Data Tables, 2011). The increase in 
prevalence is due largely in part to the improvements in the quantity and quality of antiretroviral 
(ARV) therapies available, as well as the rollout of these treatments in low and middle income 
countries. While there have been significant advances in HIV treatments and surveillance 
programs for adults, there remain many obstacles towards achieving parallel success among 
children infected with HIV. By the end of 2012, an estimated 220,000 South Africa children 
were in need of antiretroviral therapy (ART) (Antiretroviral Therapy for HIV Infection in Infants 
and Children, 2010). Efforts have been undertaken by several organizations such as the Joint 
United Nations Program on HIV/AIDS (UNAIDS), the World Health Organization (WHO) with 
UNITAIDS, and the Clinton Health Access Initiative (CHAI)  towards closing the treatment gap 
among children. Specific focus has been on improving the market limitations such as cost and 
availability. Concern for ART in regards to children is exacerbated by the increasing HIV drug 
resistance. Drug resistance is attributed to many factors including difficulty with therapy 
adherence and drug absorption along with lack of appropriate viral monitoring systems. These 
issues are highly prevalent in resource-poor settings such as South Africa. With the limited 
treatment options available, choosing the correct second-line therapy is critical, yet resistance 
testing is not readily available country-wide (Zanoni et al., 2012). This study attempts to address 
the issue of increasing HIV drug resistance among children in South Africa, highlight the South 
African national response, and explore the methods taken by the international community to 
prevent drug resistance.   
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 A substantial field of knowledge exists regarding HIV drug resistance among adults, yet 
there are significantly fewer studies which focus on children. Additionally, HIV treatment for 
children is vastly different from adults. Challenges exist in the improvement of pediatric ARVs, 
mainly the fragmentation of the pediatric market. While many ARVs are circulating the market, 
few have been approved for children. For example, although the drug tenofovir (TDF) has been 
approved for first-line treatment in adults, there is limited data on the safety of this drug for 
children; thus, there are no pediatric formulations with TDF to date (Antiretroviral Therapy for 
HIV Infection in Infants and Children, 2010). There is a dire need for safe, palatable, potent, 
heat-stable, and fixed-dosed combinations (FDCs) that can be employed in the fight against 
pediatric HIV (International AIDS Society, 2013). Finally, there is no consensus as to whether 
drug resistance testing upon surveillance of first-line HIV drug failure is cost-effective for 
children. The question in focus is whether widespread pediatric drug resistance testing is 
efficient when determining whether to switch from first-line to second-line therapies or not.  
Literary Review 
 Drug resistance is an evolving field with new studies continually being released on the 
efficacy of first-line and second-line treatments as well as the implementation of strategies to 
reduce drug resistance. One approach is to implement resistance testing to detect virological 
failure. Most commonly used is genotypic resistance testing, which can detect from a blood 
sample mutations in the HIV virus known to cause resistance to certain ARVs. It is currently 
being debated whether genotypic testing is cost-effective and whether it should be implemented 
in routine care. Three studies represent the competing viewpoints on this issue. 
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 A study published in 2012 by Levinson et al. reported on the clinical and financial impact 
on genotypic testing at first-line ART failure. By using the Cost-Effectiveness of Preventing 
AIDS Complications International model of HIV, the researchers were able to simulate a South 
African cohort of HIV-positive adults failing first-line treatment. Their findings suggest that 
when an individual test cost less than $100 USD, genotype testing becomes extremely cost-
saving at a rate of $900 per years of life saved by treatment. However, this efficiency is 
dependent upon a rate of wild type HIV near 12% and timely results. Their rationale is that 
without genotypic testing, virological failure prompting a switch to second-line treatment is 
based on CD4 count. However, patients failing ART with wild type virus often have poor 
adherence rather than drug resistance. Genotypic testing may distinguish patients with true 
resistant HIV from those who might benefit better from adherence counseling rather than a 
switch to expensive second-line therapy (Levison et al., 2013). It is important to note that this 
simulation was for South African adults rather than children. It is plausible that genotypic testing 
is not as cost-effective in children.  
 A 10-year review of the patterns of HIV drug resistance in South Africa conducted by 
Kiepiela et al. concluded that genotype testing is cost-saving for those failing second-line 
treatments and cost-neutral for those failing first-line treatments. Due to the results, the 
researchers suggested that this testing be included in routine care (2014). A possible reason for 
the neutrality among patients failing first-line is that second-line treatments are becoming more 
affordable and it may or may not be worth waiting to switch treatments until test results are 
analyzed. There are several benefits of genotype testing proposed by Lessells et al. in 2013 
including most importantly identifying the root cause of virological failure such as poor 
adherence, interruption of therapy, or poor absorption of the medications (2013).  
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 The final viewpoint is that genotypic testing is not cost-effective. In October 2014, 
Phillips et al. reported that despite the assumptions of a relatively inexpensive process, resistance 
testing at first-line failure when deciding whether to switch to second-line therapy was not cost-
effective. They used a similar method as Levinson et al. by simulating a model of HIV 
progression and the effects of ART in a low-income setting. Patients with virological failure but 
no resistant mutations have better outcomes when they switch to second-line treatment rather 
than not, because it is extremely hard to change patterns of adherence. In addition, second-line 
therapies are more forgiving of weaker adherence due to their higher potency (Phillips et al., 
2014). A major argument against implementing widespread HIV drug resistance testing in low-
income settings is that clinical and institutional infrastructures are already weak. Priority in 
regards to funds, human resources, and technology should be directed towards testing for the 
infection and providing treatments.  
 After a review of this literature, it is clear that there is a lack of consensus regarding the 
cost-benefit factor of genotypic resistance testing among children providing a rationale for this 
study.  
Research Methodology 
 In order to answer the research question, primary and secondary sources were gathered 
using a variety of methods. For secondary sources, a search was conducted on databases such as 
PubMed, Google Scholar, and Web of Science with the key words “HIV drug resistance”, 
“Children”, and “South Africa”. These searches revealed many studies conducted on these topics 
as well as government documents. Two main documents discovered were the “Consolidated 
Guidelines on the use of ARV Drugs for Treating and Preventing HIV Infection June 2013” 
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published by WHO and the “South African Antiretroviral Treatment Guidelines 2013” published 
by South Africa’s Department of Health. A comparison was made to determine whether drug 
therapies in South Africa follow the guidelines of WHO. Primary sources include the personal 
interviews conducted by the researcher with various experts in the field of HIV drug resistance. 
Interviewees were first contacted by email to determine whether they were available to 
participate. These emails contained detailed information including the purpose of the study along 
with a request for participation by means of an interview ranging from 30 minutes to one hour.  
 A combination of methods was employed to collect the data, but it was mainly a 
qualitative approach. The researcher started with observations of the problem, HIV drug 
resistance among children, and formulated a theory about drug resistance testing from the 
findings. Interviews were semi-structured in that questions were prepared ahead of time, but the 
participants were encouraged to take the conversation in different directions so that it was a 
natural process. In addition, the process of drug resistance was interpreted from the participant’s 
perspective. Although this is a case study of country, it is the researcher’s hope that a theoretical 
generalization can be made with the results so that they can be applicable to not only South 
Africa but other low and middle-income countries.  
 All ethical considerations were taken in this study. No harm was inflicted on the research 
participants and each was given a detailed description of the research prior to involvement. 
Confidentiality and privacy were ensured by gaining informed consent to use interviewees’ 
names and other identifiable information. Consent was also given before notes were taken. 
Interviewees had the opportunity to not answer a question or to stop the interview at any time. 
Special consideration was taken since this study was focused on one country. Information was 
gathered and analyzed on South Africa strictly for educational purposes without the intent of 
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embarrassment. Finally, children are a vulnerable population. Although the topic is HIV drug 
resistance among children, none were used as participants in this research.  
Analysis 
Pediatric HIV in South Africa 
 Overall, South Africa has a generalized HIV epidemic, with greater than one percent of 
the population infected. Although the epidemic has stabilized over recent years, the prevalence 
rate is still extremely high, at around 19.1% for adults aged 15 to 49 years. Compared to this 
alarmingly high level, the pediatric prevalence rate among those aged 0 to 14 years was only 2.4 
percent in 2012 (Human Sciences Research Council, 2014). However, there is a wide treatment 
gap among that 2.4 percent living with HIV. In Sub-Saharan Africa, a region accounting for 91% 
of the global pediatric treatment need, coverage is extremely low at around 21% (UNAIDS Data 
Tables, 2011). With the 2013 estimates now at 360,000 South Africa children living with HIV, 
there is a clear motivation to provide the necessary treatment (HIV and AIDS estimates, 2012).   
PMTCT Strategies  
  In the last decade, there have been strong efforts in South Africa to prevent mother-to-
child transmission (PMTCT). These practices include primary prevention of transmission, 
prevention of unintended pregnancies, and equitable access to testing, counselling, and ART 
(Global guidance on criteria, 2014). In 2002, the South African Department of Health launched 
national PMTCT programs. Policies have been revised several times with new provisions 
including a shift towards an increase in infant HIV testing at an earlier age (Barron et al., 2013). 
At inception of the program, single-dose nevirapine was used as the standard of PMTCT 
maternal care in South Africa. However, this therapy is strongly associated with non-nucleoside 
reverse transcriptase inhibitor (NNRTI) resistance among HIV-infected infants. When the WHO 
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recommended combination regimens for these programs in 2006, South Africa scaled up its 
standards to include these new regimens.  
 Overall, there has been an evolution in PMTCT strategies to shift towards earlier 
treatment. Now the preferred therapy for mothers, Option B+ suggests that all pregnant and 
breastfeeding women with HIV start ART immediately after diagnosis and maintain their therapy 
for the duration of the mother-to-child transmission risk (Consolidated Guidelines, 2013). 
PMTCT efficacy is strongly dependent on how quickly the mother is diagnosed, whether she 
continues treatment after birth, and how quickly the infant is tested (G. McCullough, personal 
communication, October 30, 2014). For these reasons, WHO has identified early identification of 
HIV-infected children as vital for PMTCT success. When proper PMTCT methods are 
employed, HIV transmission to the infant is reduced from 35% to about 2 – 20% (Antiretroviral 
Therapy for HIV Infection in Infants and Children, 2010). By reducing the viral load to 
undetectable levels in the infected individual, risk of transmission is significantly reduced. 
 The new PMTCT strategies dramatically reduce the number of children who acquire 
infection, but among those who do become infected, NNRTI resistance prevalence is high. A 
study conducted in 2011 in Johannesburg, South Africa included 230 recently infected HIV-
positive children under the age of two. Two-thirds of the participants had been exposed to either 
maternal and/or infant PMTCT. Of those exposed, 56.8% had NNRTI mutations while 14.8% 
had nucleoside reverse transcriptase inhibitor (NRTI) mutations (Kuhn et al., 2014). One 
wonders how problems with adherence play a role in the presentation of resistant mutations and 
whether what drug resistance testing in this study would have revealed.  
 Finally, with a focus on 22 priority countries including South Africa, WHO created a 
Global Plan towards the elimination of new HIV infections among children. The goal is to 
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“reduce the number of new HIV infections among children by 90%” and to reduce the rate of 
mother-to-child transmission to less than 5% (Global guidance on criteria, 2014). There is a 
clear need to address the millions of infected children so that they can live normal lives, but it 
also just as important to prevent children from getting infected.  
Pediatric HIV Drug Resistance 
 With the increased access and exposure to ART, the number of infants and children with 
HIV drug resistance (HIVDR) is on the rise. The study “Pediatric Response to Second-Line 
Antiretroviral Therapy in South Africa” found that 9.1% of the 880 children involved 
experienced drug failure to their first-line therapy after a median time of 95 weeks (Zanoni et al., 
2012). Since ART is a lifetime treatment, it is alarming that this many children needed to switch 
regimens so soon after treatment initiation. The cost and pill burden is high for these children 
requiring second-line treatment, and their therapy options are dramatically limited.  
 HIVDR among children can result in two ways.  Transmitted drug resistance, or TDR, 
occurs when a drug-resistant strain is spread from mother to infant (Antiretroviral Therapy for 
HIV Infection in Infants and Children, 2010). A study conducted between 2005 and 2009 
suggests that TDR rates vary among South African provinces. The KwaZulu-Natal province has 
the highest rates with up to 15% of transmitted resistance to the NNRTI drug class (Hunt et al., 
2012). These high rates are contrasted with the prevalence in the Western Cape Province at 3.8% 
(South African National AIDS Council, 2011). This increases the difficulty in universalizing 
treatment procedures across South Africa.  
 The other source of HIVDR is acquired drug resistance or ADR. ADR occurs when 
mutations of the viral genetic code appear following administration of pediatric ART. The HIV 
virus replicates so quickly that mutations in the genetic composition render the antiretroviral 
drugs ineffective against those mutated strains. This type of resistance among children is most 
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commonly attributed to poor adherence, use of suboptimal treatments, or to toxicity and 
absorption issues. Several studies support the notion that poor adherence to ARTs is a social 
predictor of virological failure, defined by WHO as a “plasma viral load above 1000 copies/ml 
based on two consecutive viral load measurements” separated by 3 months of treatment (Barth et 
al., 2011 & Consolidated Guidelines, 2013). Due to the rapid replication of this retrovirus and 
longevity of treatment plans, mutations will occur, even among those who follow therapy 
regimens perfectly. In addition there is also the issue that drug resistance can develop at any 
stage of treatment. Multidrug resistance among children who have taken multiple ART is 
increasing (Antiretroviral Therapy for HIV Infection in Infants and Children, 2010).  With the 
limited data available, there is little to base national recommendations regarding treatment plans.  
Types of HIV Drug Treatments 
 Among the therapies available are the three classes of antiretroviral drugs including 
NRTI, NNRTI, and protease inhibitors (PI).  In 2013, the WHO updated the Optimal 
Formulatory List for pediatric HIV medications. This list includes ten drugs with their drug class, 
suggested formulation, and dosage (UNICEF, 2014). Although a consolidated list simplifies the 
decision of which ARTs to use, it also limits the options available once a treatment becomes 
ineffective. Among the NRTIs, the only drug listed by itself as optimal is a thymidine analogue 
named zidovudine or AZT. This drug is generally well-tolerated among children but has been 
linked to metabolic complications such as anemia. The other thymidine analogue stavudine or 
d4T is associated with lactic acidosis and therefore, has been phased out of use since 2010. Two 
other NRTIs are used among children but are found in fixed-dosed combinations, that is, they are 
mixed with other drugs to make appropriate formulations for children. Optimal combinations 
include those of AZT with lamivudine (3TC), a cytidine analogue with a strong safety and 
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tolerability record, and those of AZT and abacavir (ABC) (Antiretroviral Therapy for HIV 
Infection in Infants and Children, 2010). 
 For the NNRTI drug class, the two optimal medications are efavirenz (EFV) and 
nevirapine (NVP), both often found in FDCs. The final drug class, the PIs, operate by inhibiting 
the activity of protease, an enzyme used by the HIV during the production of new viral 
components. The only optimal PI is ritonavir-boosted lopinavir (LPV/r). While LPV/r is 
regarded as the most appropriate regimen for infants, it is poorly adapted for children in that it is 
only available in liquid form, has high alcohol content, and is heat sensitive requiring 
refrigeration (Better HIV Treatment for Infants, n.d.). 
 The difficulties in choosing a medication go beyond possible side effects and toxicity. 
When picking among a drug class, such as the NRTIs, the first-line choice impacts the 
availability of drugs that can be used for second-line, should the child need to switch. For 
instance, since both AZT and d4T are thymidine analogues, failure of either results in the 
replication of thymidine analogue mutations (TAMs). When multiple TAMs accumulate, the 
functionality of other drugs as second-line therapies such as ABC is reduced. On the contrary, a 
child who becomes resistant to ABC on first-line will not have any TAMs and has the option to 
take AZT or d4T as second-line (Antiretroviral Therapy for HIV Infection in Infants and 
Children, 2010). 
Challenges with Pediatric HIV Care 
 There are many social and physical challenges to providing the correct care for HIV 
positive children and ensuring they adhere to their regimens. In South Africa, as in other Sub-
Saharan countries, there is a significant lack of human resources. At the forefront is the shortage 
of staff adequately trained to manage HIV (Meyers et al., 2007). This ultimately leads to the 
inability to diagnosis and treat children correctly. In this country, around 15% of public health-
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care facilities are unable to initiate HIV treatment (Barron et al., 2013). Doctors in these areas 
must refer patients to other facilities, subsequently increasing the complications for the mother in 
regards to access to treatment. Currently, there is a lack of good diagnostics with HIV 
surveillance and monitoring. Improving diagnostic systems is crucial, because when a mother is 
monitored, health officials can ensure that the child is receiving the correct dosing at the right 
times.  
 Other physical factors include limitations in the market for pediatric HIV formulations. 
The consistent consumption of necessary medication is hindered by the “poor palatability, high 
pill burden or liquid volume, frequent dosing requirements, dietary restrictions and side-effects” 
that accompany the available medications (Antiretroviral Therapy for HIV Infection in Infants 
and Children, 2010, p.78). In addition, formulation is dependent on weight. In settings where 
resources are limited, caregivers try methods such as halving the dose of adults, yet this is 
dangerous, because the actual dosage is unknown.  
 In a series of workshops held in the provinces of KwaZulu-Natal and Gauteng during 
November 2012, parents and caregivers of children receiving ART identified the main 
challenges in adhering to medications. One challenge was not understanding the need for taking 
ART or how to properly administer the regimens. The financing of attending hospitals and other 
care facilities also greatly affected access to ARVs. Additionally, several parents had difficulty 
obtaining their child’s birth certificate or proving legal guardianship so they could not receive 
state aid. Final barriers include frequent appointments and lack of confidentiality among health 
care workers (Ngobeni-Allen et al., 2013). All of these factors expose the need for an integrated 




 Not only are their problems with human and diagnostic resources, but there are also 
social factors contributing to the challenges in pediatric HIV care. In many circumstances, the 
mother is aware of the positive status of her child but disclosing this information to her husband 
would create many problems within the home. In addition, due to the stigma, discrimination, and 
anxiety surrounding a diagnosis of HIV, many mothers chose not to disclose the status of their 
child to their friends or community. As a Technical Director for UNITAID, Gelise McCullough 
travels to countries to assess the strength of health care facilities. She gave the example of a 
woman and her HIV positive child living at a hostel in the Kibera village in Kenya. For fear of 
discrimination, this mother hid her child’s medication and gave them haphazardly when no one 
was watching. Since the therapy was not followed religiously, her child is now on second-line 
treatment (G. McCullough, personal communication, October 30, 2014).  
 Another factor to this issue is that drug resistant strains develop quickly in children, and 
progression of HIV occurs rapidly during the first few months of an infant’s life. In a South 
African study conducted in 2008, up to 80% of infected infants well at 6 weeks of age had 
progressed by 12 months of age to become eligible to start an ART (Volari et al., 2008). Another 
study conducted in Mali on HIV positive children observed that nearly 25% of the cohort 
developed resistance to HIV after 6 months on ART (Germanaud et al., 2010).  Once again, 
appropriate diagnostics at an early age are necessary in order to get children started on ART as 
soon as possible. With the greater push to initiate ART earlier, there is the unknown of how the 
virus and treatment will affect the child as he or she grows. Mrs. McCullough notes that adults 
can have 50 years of life on ART, but this timeline is undetermined for children (G. 
McCullough, personal communication, October 30, 2014).  
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 It is easy to say that better diagnostics are needed; however, this is difficult to accomplish 
because infants require different tests than older children and adults. Those older than 18 months 
can be given a serological test to determine HIV status. This type of test detects any antibodies 
the patient’s body has developed against HIV. However, this test cannot be performed on infants 
younger than 18 months since the test cannot determine the mother’s antibodies from the 
infant’s. For this group, virological tests must be performed. This test detects the molecular 
components of the HIV including its RNA (Antiretroviral Therapy for HIV Infection in Infants 
and Children, 2010).  
  As previously mentioned, HIV prevalence varies among sexes, age groups, and location. 
Currently in Sub-Saharan Africa, there is terrible adherence among teenagers. Mothers leave 
their 12 year old children in charge of their own medication which leads to problems down the 
line. After a few years on treatment, many of these children interrupt their therapies and go on 
“holidays”. This term is taken from an HIV-positive girl interviewed by Mrs. McCullough in 
Kenya. She explains that many adolescents start to feel better and wonder of a life without HIV 
medication. This is obviously a major problem since ART is a lifetime treatment and must be 
taken religiously for it to be most effective (G. McCullough, personal communication, October 
30, 2014).  
Opportunities for Pediatric HIV Care 
 At first glance, the challenges seem daunting; however, there are many opportunities for 
success in regards to pediatric HIV treatment. Despite the treatment gap among children, South 
Africa has the largest ART program covering nearly 1.79 million patients primarily through the 
public health sector (Kiepiela et al., 2014). Since this country is classified as middle-income, it is 
fairly self-sufficient in regards to meeting the health needs of its population. In addition, the 
governmental response to the HIV epidemic has undergone a “complete transformation”. In 
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2009, President Jacob Zuma broadened HIV drug access to pregnant women and infants and 
encouraged an earlier initiation of ART. The increased capacity of South Africa to manage HIV 
is seen in that most of the treatment is now funded by the government (L. Nelson, personal 
communication, November 17, 2014).  
 Another advantage is that the fight against pediatric HIV is a consolidated effort among 
the international community. Among the numerous actors are UNITAIDS, the United States 
President’s Emergency Plan for AIDS Relief (PEPFAR), UNAIDS, the Global Fund, and CHAI. 
In a combined effort, each can contribute differently in order to maximize the public health 
impact.  
 That same cohort of caregivers who identified barriers to ART access and adherence also 
provided supportive factors towards access. Participants offered that observing the improvement 
of their child’s health after being on ART improved their confidence in administering the 
regimen and the reasons for adherence. Additionally, attending treatment classes and talking to 
other parents improved their understanding of ART (Ngobeni-Allen et al., 2013). Lisa Nelson 
with the Global Fund agrees that peer support and working with communities is vital in 
increasing adherence. Other suggested strategies for improved adherence include training of 
health care workers, counselling services and family clinics where mother and child can receive 
access simultaneously. By increasing support for these women, they are more freely able to 
accept their status or the status of their child and move on to treatment.  
 In addition to improving PMTCT strategies, South Africa has also devoted significant 
resources into other testing and treatment options. In 2004, the South African Comprehensive 
HIV and AIDS Care, Management and Treatment Plan made highly active ART (HAART) more 
available to the masses. Two years later, early diagnosis of HIV in infants was made possible 
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with the introduction of DNA polymerase chain reaction (PCR) testing. Huge strides have been 
made since then to increase access to the testing. Although PCR testing capacity was only at 
27% in 2006, it dramatically increased to 70.4 % in 2011 (Meyers et al., 2007). With a large 
ART program, the opinions of those immediately impacted by the HIV epidemic, and the 
increase in diagnostic tools, South Africa is positioned to reduce transmission and improve the 
quality of lives for those infected.  
 The National HIV Prevalence, Incidence, and Behavior Survey conducted by the South 
African Human Sciences Research Council used HIV incidence testing to measure the number of 
new cases (2014). This novel approach alone shows the increased national ability to monitor this 
epidemic. Previous surveys only had the ability to measure prevalence, or the number of people 
infected with the virus. The overall results point to a decline in HIV incidence since its peak in 
2005; however, the decline is not as prominent as hoped.  
 In 2009, Dr. Reuben Granich and his team of researchers from UNAIDS suggested a 
unique approach towards eliminating HIV infection among the South African population. There 
modeling suggests that providing universal, voluntary HIV testing and immediate ARV therapy 
for those who test positive along with existing preventative measures could “reduce the 
prevalence of HIV to less than 1% within 50 years”; thus, changing the generalized status of the 
epidemic (Granich et al., 2009). The driving force behind the success of treatment as prevention 
is that if you can get viral suppression down in a population, than transmission should also be 
reduced (R. Granich, personal communication, November 7, 2014). This study shows major 
promise in the future of the HIV epidemic in South Africa, yet it hinges on having access to 




WHO Pediatric ART Guidelines  
 In an effort to provide universal and comprehensive HIV treatment, the WHO produced 
the “Consolidated Guidelines on the use of ARV Drugs for Treating and Preventing HIV 
Infection” in June 2013 as an update of the 2010 guidelines. The influence behind these 
guidelines is strengthened by the fact that many institutions contributed to their development 
including the South African Medical Research Council. WHO takes a humanitarian approach 
towards the HIV epidemic by recognizing access to HIV prevention, treatment, care and support 
as a universal right to health (2013). It runs in full circle in that the denial of human health rights 
increases the risk of HIV infection, and “HIV infection increases the risk of human rights 
violations” (National Strategic Plan on HIV, 2012, p.30).  
 The complexity of pediatric HIV can be seen in the WHO recommended first-line and 
second-line therapies provided in Table 1. The recommendations are dependent on age, and 
second-line options are, as previously mentioned, dependent on what first-line therapy was 
prescribed. Of most importance is the use of a LPV/r-based regimen as first-line ART for all 
HIV-infected children younger than three years, regardless of exposure to ARVs during a 
PMTCT strategy (Consolidated Guidelines, 2013). Several studies support the recommendations 
to use LPV/r rather than an unboosted PI regimen. One such study conducted by van Zyl et al. 
found resistance mutations in 12 of 17 patients on a single PI therapy compared with 1 of 13 
patients on an LPV/r-based regimen (2009).  Von Wyl et al’s study in 2013 further supports the 
idea that “ritonavir boosted PI regimens allow for more potent viral suppression,” because they 
exhibit a high genetic barrier to resistance (2013). The WHO recommendations are extremely 
useful for national health departments when making policy; however, the challenges of pediatric 
HIV care rule in that if certain drugs are not available, they cannot be employed in ARTs, 
regardless of how optimal they are. In addition the recommendations of a PI-based regimen over 
 an NNRTI-based regimen are supported by the findings of Pillay et al. Of the 73 patients on a 
NNRTI regimen, 80% had both NNRTI and NRTI mutations while only 1 in 17 patients on a PI 
regimen had resistance mutation (
Table 1. Summary of recommended fi
(including adolescents) 
From the “Consolidated Guidelines on the use of ARV Drugs for Treating and Preventing HIV Infection June 2013”
 
 In addition to advice on what to prescribe, these guidelines also 
when to initiate ART in children. The major changes from the 2010 edition ar
be initiated among infants and children
stage or CD4 cell count, those older than 5 years 
among all HIV-infected children in WHO clinical stages 3 or 
(Consolidated Guidelines, 2013)
2014).  
rst-line and second-line ARV regimens for children 
give recommendations on 
e that ART should 
 five years of age or less, regardless of WHO c
of age with a CD4 count ≤500 cells/mm











 Each of these recommendations has certain important implications. First, for those 
younger than 5, disregarding clinical stage and CD4 count widely opens access to treatment. 
Perhaps the most significant change is that in treatment eligibility from a CD4 of ≤350 cells/mm3 
to ≤500 cells/mm3 for those older than 5 years of age. It is much more inclusive; however, not 
many countries have the capacity to manage this switch yet as viral load testing is not readily 
available (G. McCullough, personal communication, October 30, 2014). Weak health care 
capacity is also a reason for the third recommendation. In regions where viral load or CD4 
testing is not readily available, clinical staging is the only diagnostic tool to use. 
South African National Guidelines 
 Even though the WHO guidelines are comprehensive, they are certainly not implemented 
evenly across all countries. Additionally, it is a lengthy process to develop and implement policy 
at the national level, and even more time passes before written policies are accurately reflected in 
program implementation and clinical practice (R. Granich, personal communication, November 
7, 2014). Managing these changes, such as the new ART eligibility CD4 count, is difficult for 
many low and middle-countries. Specifically with this change, the influx of eligible patients puts 
a strain on the health care system. However, South Africa has been diligent in keeping up with 
the changes made and its policies are almost in full compliance.  
 For children under three years of age, the recommended first-line therapy is ABC, 3TC, 
and LPV/r. For those older than three years of age, it is ABC, 3TC, and EFV. Second-line 
therapies are also in accordance with the WHO in that the recommended regimen is AZT, 3TC, 
and LPV/r. The complete suggested regimens for infants and children are outlined in Table 2 
(Department of Health Republic of South Africa, 2013). The Department of Health is also 
following the phase out of d4T by recommending a switch to ABC if viral loads are 
undetectable.  
 Table 2. Summary of South African nationally 
 regimens for infants and children
  Taken from the South African National Antiretroviral Treatment Guidelines 2013
 In addition to the standardized regimen
infants and children living with HIV. 
CD4 count, WHO clinical staging, and TB status are performed at initial diagnosis of HIV and at 
follow up appointments (Department of Health Republic 
are necessary in order to monitor the development of HIV; however, a major problem is getting 
patients to come to the clinics for follow
clinic and the long lines deter many mothers from bringing their children 
Despite this, by being in accordance with the WHO guidelines, these national
recommended first-line and second
 
s are the national monitoring procedures 
Routine measurements of weight, height, development, 
of South Africa, 2013). These protocols 
-up appointments. The long distances from home to 
in for appointments. 
 policies will 
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expand the number of children able to get treatment and will provide support for proper 
adherence to their therapies (R. Granich, personal communication, November 7, 2014). 
 South Africa does lag behind the WHO in several areas as portrayed in Table 3. For ART 
initiation eligibility for asymptomatic people, South Africa plans to move eligibility to a CD4 
count of ≤500 cells/mm3; however, it has yet to be implemented in the national strategy (The 
Global Database, 2014). This exposes the disparities between the Northern and Southern 
approach to HIV treatment. In the United States and other Western countries, treatment is given 
at a higher CD4 count, yet in areas where HIV is most prevalent, treatment is not initiated until a 
lower CD4 count. Similar disparities exist for pregnant women in that Option B+ is the standard 
for Northern countries while in South Africa, a CD4 count of ≤350 cells/mm3 is required for 
ART initiation. Finally, by decentralizing ARV distribution to the community level, more people 
have access to treatments. This is especially necessary for South Africa since the clinics cannot 
manage the full demand for ART.  
Table 3. A Comparison between WHO and South African National ART Treatment Guidelines   
Policy WHO Guidelines  
(Consolidated Guidelines, 2013) 
South African Guidelines 
(Department of Health Republic of 
South Africa, 2013) 
ART Initiation Eligibility for 
Asymptomatic People 
CD4 count ≤500 cells/mm3 CD4 count ≤ 350 cells/mm3 
ART Initiation for pregnant 
women 
Irrespective of CD4 count 
(Option B+) 
CD4 count ≤ 350 cells/mm3 
Frequency of CD4 
Monitoring  
Every 6 months  12 months of age 
Frequency of Viral Load 
Monitoring  
Month 6, 12, 24 and yearly 
after month 24 
Month 6, 12, 24 and yearly 
after month 24 
Nurse Initiation of ART? Yes Yes 
ARV Dispensing at 
Community Level? 
Yes No 
When to Initiate ART for 
Infants? 
Immediately regardless of 
ARV exposure 
Exposure to ART: NVP at 
birth then daily for 6 weeks 
No exposure to ART: NVP as 






 The multilateral fight against HIV/AIDS includes many actors in the international 
community including WHO, UNAIDS, UNITAIDS, the United Nations Development Program 
(UNDP), the Global Fund, CHAI, and PEPFAR. This list is not exhaustive as there are countless 
others working in collaboration. The intertwining relationships among these organizations are 
delicate in that desires and interests have to match in order for there to be effective treatment 
development and distribution, along with policy development.   
 Although WHO has developed the bulk of international recommendations for HIV ART, 
UNAIDS provides global leadership in the response against this epidemic. This organization gets 
some funding from PEPFAR, and there is collaboration with UNITAIDS on providing funds for 
testing and with CHAI on monitoring the epidemic (R. Granich, personal communication, 
November 7, 2014). The Global Fund a new funding model as of last year where the ability of a 
country to pay for health services and their need are dually considered when grants are given. So 
that countries no longer compete for grants, money is set aside for each country until it can 
submit a good application for a grant. There are nine active Global Fund grants in South Africa 
targeted towards HIV/AIDS, all managed by the country coordinating mechanism. This focal 
point proposes what to do with the money, decides when to apply the grants, and decides who 
the principle recipients of care are (L. Nelson, personal communication, November 17, 2014). 
 Many of the projects of UNITAIDS are focused on HIV treatment, and although only one 
is directly active in South Africa, a lot of the work benefits this country. One of the largest 
UNITAIDS projects titled “Pediatric HIV/AIDS Project” ran from 2006-2014. With a budget of 
$418,474,634 USD and CHAI as the lead implementers, this effort has vastly improved the 
pediatric ARV market. By increasing the confidence in pharmaceutical companies to invest in 
pediatric ARVs, antiretroviral prices have decreased, and there are more generic medications and 
 adapted FDCs. The dramatic decrease in pediatric HIV treatments can be seen in Figure 1. In 
2006, a leading ARV cost $252 USD while in 2011, this price dropped to 
per year (ppy) “due to high-volume drug purchas
Another major strategy for market intervention
decentralized diagnostics. This is 
and Young Children Program” implemented by the Drugs for Neglected Diseases Initiative. 
Point-of-care treatment, such as portable machines to measure CD4 count, 
treatment closer to the site of patient care so that results are received
(Better HIV Treatment for Infants
technology such as viral load testing and early infant diagnosis
follow the development of the virus and the effectiveness of drug formulation
Figure 1. Median price (US$ ppy
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 Improving the market for second-line treatments is also a key area of work for 
UNITAIDS. For adult regimens, prices have fallen 73%:  In 2006, the leading second-line 
regimen of TDF, 3TC, and LPV/r cost $1,500 USD ppy. Today, the price is now $527 USD ppy 
(Better HIV Treatment for Infants, n.d.). These advancements are promising in the effort to 
provide access to every patient in need; yet, it will be interesting to see whether pediatric second-
line regimen prices will follow suite in similar reductions. Before this can be accomplished, there 
needs to be a more competitive market for second-line therapies for children. Finally, WHO has 
identified several key formulations not available for children including ritonavir-boosted 
darunavir (DRV/r), a combination that could be used for children failing a first-line regimen 
based on LPV/r (Paediatric HIV Treatment Initiative, n.d.).  
WHO and South African Response to HIVDR  
 In regards to HIVDR, the WHO recommends country-wide surveillance and monitoring 
systems for the pediatric HIV population (Antiretroviral Therapy for HIV Infection in Infants 
and Children, 2010). South Africa, being more self-sufficient in the HIV fight, has a stronger 
capacity than most Sub-Saharan African countries to manage these systems. New reports 
released by the WHO include strategies to support the sustainability of HIVDR surveillance 
programs. This global strategy encompasses assessment tools for TDR surveys, ADR surveys, 
and Surveys of HIVDR in infants younger than 18 months of age, all of which require HIVDR 
genotyping. The goal of each survey is to inform selection of optimal therapies for the target 
populations (Meeting Report: Implementation & Sustainability, 2014).  
 For TDR, it is recommended that countries incorporate surveillance into existing routine 
diagnostic testing activities. The ADR surveys will assess levels of viral suppression at two key 
time intervals: 12-24 months and 48–60 months after treatment initiation. The final survey 
involving pediatric populations aims to inform selection of optimal first-line ART. Success of 
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this survey is linked to the strength of early infant diagnostics in that if infants are quickly 
diagnosed, they can have immediate access to optimal therapies (Meeting Report: 
Implementation & Sustainability, 2014). A question to pose is whether there are any surveillance 
systems in place to measure HIVDR among children failing first-line ART? If not, is it feasible 
to initiate such programs into South Africa’s health care system?  
 Included in this report are the draft HIVDR surveillance priorities and plans established 
by South Africa for 2013-2017. A working group of a clinical team, laboratory group, and 
epidemiology development group will manage these monitoring surveys. Funding will be 
temporarily managed by the CDC and Global Fund until they can be “integrated in [the] national 
health budget”.  These surveys and genotype testing are a great tool in the mapping of resistance 
patterns; however, there are several limitations to this approach in South Africa. For example, 
data in this country is available through over 4,000 clinics, yet many of these clinics operate in 
paper-based reporting. There is a need to centralize all reporting so that samples are unbiased and 
reporting is accurate. Additionally, TDR surveys are currently provincial (Meeting Report: 
Implementation & Sustainability, 2014). Many question whether a nationally representative 
estimate of TDR can be obtained from this method. The solution might be regional surveillance, 
yet the costs are too large to justify this approach.  
Drug Resistance Testing 
 The idea behind drug resistance testing is that sequencing a virus’s genome can be used 
to optimize the use of ART in individuals experiencing virological failure. This test detects 
changes in the viral genome, in the form of mutations, which make the individual less receptive 
to the medication (Imperial College London, 2013). It can also be used to determine whether the 
underlining issue is drug-resistant mutations or lack of adherence. Although this is an extremely 
useful tool when tailoring treatments, each of the participatory experts in this study commented 
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that it is not a cost-efficient option for South Africa at the current moment. A genotypic test 
today costs about $300. Referring back to Figure 1, one can see that the median price of the 
recommended pediatric first-line therapy of ABC, 3TC, and LPV/r is slightly more than $250 
ppy. Since one test costs more than a year’s worth of treatment, it is unlikely that genotypic 
testing will be implemented nation-wide in the near future. However, if the cost of such tests 
decreased, there would be more incentive to increase their use. Dr. Nelson identified the need for 
a low cost strategy with drug resistance testing and provided the example of the rapid GeneXpert 
test which has had huge success in detecting tuberculosis and Rifampicin resistance (Personal 
communication, November 17, 2014). Due to the huge issue of mal-adherence, sequencing the 
genome of the HIV virus would keep patients with perceived virological failure but no resistant 
mutations from switching to a more costly second-line therapy.  
 Lessells et al weigh the opportunities and difficulties of implementing widespread HIV 
genotypic testing. They argue that as more formulations become available for use, the demand 
for individualized resistance testing will increase to aid clinics in the “management of virological 
failure.” The benefits of drug resistance testing include the conservation of first-line therapies 
and targeted interventions to resolve adherence issues. They also posit that since third-line 
therapies are so expensive, it is worthwhile to invest in a genotype test so that the patient has a 
smaller risk of virological failure (2013). 
 Over the last decade, laboratory capacity in South Africa has grown tremendously where 
17 laboratories now perform nearly two million viral load tests per year. Advancements in the 
area of resistance testing have been made by The Southern African Treatment and Resistance 
Network to reduce the cost of sequencing and number of sequencing primers. An expansion of 
training and teaching for health workers will be required to accommodate for the rise in technical 
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ability needed (Lessells et al., 2013).  Despite the success, it is important to remember that 
statistics do not always portray the reality of the situation. For instance, it is not only about how 
many tests are performed, but who is actually being tested (D. Tarleton, personal 
communication, November 13, 2014. Are the targeted populations, such as young women, being 
reached by these services? 
 In one of the largest studies of adult HIV drug resistance in South Africa, 86% of the 222 
enrolled participants with evidence of virological failure from a first-line ART regimen had at 
least one drug resistance mutation. Each participant was given a genotype test to determine the 
presence of drug resistant mutations. This study conducted fairly recently between December 
2010 and March 2012 also reported that one in seven had complex resistance patterns “with the 
potential to limit the efficacy of the standard second-line ART regimen” (Manasa et al., 2013, 
p.4). Although some might argue that these resistance tests are unnecessary since the majority of 
participants had confirmed drug resistance, yet this study reveals that one in seven could have 
difficulties responding to standard second-line care. Knowing this ahead of time allows medical 
workers to prescribe a therapy, if the drugs are available, which have the greatest chance of 
achieving viral suppression (Manasa et al., 2013). The results from this study are widely 
applicable to South African adults, but can the same be said for infants and children and are there 
other benefits or complications with genetic testing among a younger population? 
Recommendations for South Africa Department of Health 
 In order to improve performance of ART, testing must be coupled with counseling. With 
the target for 2016 of 30 million men and women tested and counseled for HIV, South Africa is 
well on its way to achieving access to both services. Another component of this national strategic 
plan to end HIV is the bottom-up approach to governance. Reporting and monitoring of HIV will 
“start at ward level through districts”, go to the provincial level through Provincial AIDS 
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Councils, and end at the national level through the South African National Aids Council. The 
hope is that a clear framework for policy implementation will guide this entire process (National 
Strategic Plan on HIV, 2012).  
 One way to address the human rights issue of HIV/AIDS is to tackle the stigma and 
discrimination associated with a diagnosis. Efforts must be made at the national level for changes 
to be seen at the provincial and district level. Yet, it is difficult to make laws targeting human 
behavior. It cannot simply be a regulation against discrimination. There must be proper 
enforcement which will require a scale-up of existing systems. One suggestion is to use media to 
raise awareness of this problem. However there are complications with this approach, because 
individuals might disregard the message, viewing them as inapplicable to their lives. Another 
suggestion is to increase HIV education and peer support so that the population is more 
knowledgeable of the epidemic and how discrimination can lead to poor adherence and drug 
resistance.  
 Reducing stigma and discrimination is also linked to the idea of prevention as treatment. 
With the subject of drug resistance, this concept is more upstream. If a mother never got 
infected, she would never transmit to her kids, and that child would never deal with the problem 
of HIV drug resistance. Of the billions of dollars spent on HIV in 2012 in South Africa, only 
10% was for prevention (Human Sciences Research Council, 2014). South Africa must invest 
more heavily in preventative measures so that these efforts match those being taken with 
treatment. Of course, an overall increase in spending on HIV would help the fight against this 
epidemic, but the issue of funding is always at the forefront. 
 A significant problem with HIV among the pediatric population in South Africa is that 
health workers are not finding the children in need (G. McCullough, personal communication, 
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October 30, 2014). Once the children are found, diagnostic tests can be performed, results given, 
and treatments prescribed. Of course, each of these areas requires improvement such as faster 
test results at the site of care and more manageable ARV formulations. Access to testing and 
treatment would dramatically increase if more medical workers were trained to deliver diagnostic 
and clinical services. This will require the South African government and Department of Health 
to increase the amount and quality of training being offered to workers.  
 An overall simplification of the system might prove beneficial for South Africa. For 
instance, providing assistance to mothers will help them get their children to the clinics. In 
addition, clinics where both mothers and children can receive ART simultaneously will 
incentivize mothers to visit. With the improvement of the pediatric first-line ART market, there 
is strong hope of similar improvements with second-line and third-line regimens. Third-line 
regimens are still very much in the clinical stage. They are extremely expensive, costing around 
$3,500 USD ppy and there are very few options. Their limited availability is problematic for all 
involved. Mrs. McCullough gave an example of parents splitting pills manufactured for adults in 
half for their children’s ART (G. McCullough, personal communication, October 30, 2014). This 
is blind dosing, because the active ingredients in the pills are not distributed evenly throughout. 
Even if a child has access to third-line therapies, the challenges of the regimen are enormous. 
Some of the infected children Mrs. McCullough has visited in Kenya are taking nine pills in the 
morning and in the night (G. McCullough, personal communication, October 30, 2014). 
Simplifying this regimen with fewer pills would lead to better adherence.  
 Another issue to confront is the lack of studies among pediatric populations. There are 
many contributing factors behind this including participant accessibility, funding, and ethics. It is 
difficult to get permission and consent from not only children but their parents in order for them 
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to be a part of these trials. There is also the question of whether the money funding these studies 
would be more useful to provide testing and treatment for the millions in need. This plays into 
the ethical considerations of genotypic testing. Is it ethical to research this new form of testing in 
Sub-Saharan Africa, a region that needs the technology the most but has the least accessibility? 
Finally, you must look what ART regimens clinics have. If the stock only includes one first-line 
and one second-line option, genotypic testing provides no help (R. Granich, personal 
communication, November 7, 2014).  
 An alarming recommendation from the WHO 2013 Guidelines is that children on failing 
second-line regimen with no new drug options should “continue with a tolerated regimen” 
(Consolidated Guidelines, 2013, p.33). The initial step must be the production of third-line 
therapies. Once this is accomplished, laboratory capacity can be increased and children requiring 
this level of medication will have higher chances of survival. Yet, there is a debate over whether 
testing or treatment is more efficient in curving the HIV epidemic. Some argue that resistance 
testing is not a solution to the problem of drug resistance and advocate for reductions in the 
emergence and spread of the virus as a means of improving HIV ART programs. 
 Due to the economic implications, the author does not advise the use of genotypic testing 
in routine clinical care in South Africa. Several other limitations exist with genotypic testing 
making it less practical for today including the current fragility of the drug supply chain and the 
difficulties with “operationalizing” this service into routine care (L. Nelson, personal 
communication, November 17, 2014). However, the question lingers as to what can be learned 
from studies involving this type of diagnostics. For instance, what could we learn from a study of 
3,000 children given genotypic testing (G. McCullough, personal communication, October 30, 
2014)?  The funding could come from UNITAIDS and the cohort of children could come from 
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the Nyumbani Children's Home in Kenya operated by Sister Mary Owens. This children’s home 
already serves thousands of HIV infected children; thus, it would solve the issue of accessing 
children for studies previously mentioned.  
Conclusion 
 HIV drug resistance among infants and children in South Africa is a multi-faceted issue. 
The WHO Guidelines revised in 2013 provide many recommendations in regards to HIV 
antiretroviral testing and treatment for this population. The South African national treatment 
guidelines are, for the most part, in accordance with the WHO. However with more children 
eligible for ART, there will naturally be more drug resistance. Many nongovernmental 
organizations are working in collaboration on the fight against pediatric HIV including 
UNITAID, UNAIDS, and the Global Fund.  
 There are many areas of improvement to be made in order to reduce drug resistance. At 
the forefront is the problem with adherence. Antiretroviral therapies must be taken religiously in 
order for them to be effective. Also, the longer drug resistance goes undetected, the more 
amplified the resistance becomes. This problem can be addressed by simplifying the pediatric 
ARV market and the overall access to medications. Providing formulations in solid form, which 
taste better, and are heat stable will increase adherence. In addition, peer support and community 
outreach will encourage mothers to get their children tested and to disclose their status. South 
Africa is a unique case in that it is middle-income country and has greater laboratory services 
than neighboring countries. Drug resistance testing is a beneficial tool in that it identifies 
resistance patterns so that specified regimens can be prescribed for individuals. Yet, in South 
Africa, resources must first go to providing universal testing and treatment; therefore, this 
Hendrix 35 
 
service is not advisable in routine clinical care. Perhaps the answer lies in providing treatment as 
prevention, an area of future research with this subject.  
 Other opportunities for future research with this subject. Once the cost of genotypic 
testing decreases and when the funding is available, a large study of pediatric HIV drug 
resistance where the patients are sequenced would be extremely beneficial in the efforts to 
eliminate HIV. When viral loads are high, transmission and the burden of HIV increases. With 
drug resistance testing, patients can be put on specialized treatments to solve the problem of mal 
drug absorption, or their difficulties with adherence can be addressed and managed. The current 
situation in South Africa does not yet allow from wide-scale genotypic testing, yet, the benefits 
are definitely worth the efforts to make this diagnostic tool more accessible. Additional future 
research could include studies on how ART initiated early in life impacts that child physically 
and mentally as he grows to maturity. Limitations of this study include the lack of new raw data 









Acronym and Abbreviation List 
3TC   Lamivudine  
ABC   Abacavir  
ADR   Acquired Drug Resistance 
ART   Antiretroviral Therapy 
ARV   Antiretroviral   
AZT   Zidovudine  
CHAI   Clinton Health Access Initiative  
d4T   Stavudine 
DRV/r  Ritonavir-Boosted Darunavir 
EFV   Efavirenz  
FDC   Fixed-Dosed Combinations  
HAART  Highly Active ART  
HIVDR  HIV Drug Resistance 
LPV/r  Ritonavir-Boosted Lopinavir 
NNRTI  Non- Nucleoside Reverse Transcriptase Inhibitors 
NRTI   Nucleoside Reverse Transcriptase Inhibitors 
NVP   Nevirapine  
PDR   Pre-treatment Drug Resistance  
PEPFAR  President’s Emergency Plan for AIDS Relief  
PI   Protease Inhibitors 
ppy   Per Patient Per Year 
TAM   Thymidine Analogue Mutations  
TDF   Tenofovir  
TDR   Transmitted Drug Resistance 
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UNAIDS Joint United Nations Program on HIV/AIDS 
UNDP  United Nations Development Program 
WHO   World Health Organization  
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10/9/14          Duration: 0:15 
Today I had my first ISP Advising Session at Ecole Club Migros in Nyon, Switzerland. The 
meeting was with Dr. Alexandre Lambert. We discussed the preliminary idea for my ISP which 
was high HIV prevalence among women in South Africa. I was directed towards several NGOs 
such as UNAIDS for sources of interviews.  
10/10/14         Duration: 0:15 
I had my second ISP Advising Session at the SIT Office in Nyon, Switzerland with Dr. Heikki 
Mattila. We talked about the final proposal which I had submitted earlier. My topic was still why 
there is a higher HIV infection rate among women than men in South Africa. I was told that my 
project passed the ethics review board and that I could begin my research.  
20/10/14         Duration: 4:30 
I started my research today by searching the internet for credible secondary sources in the area of 
gender and HIV infection in South Africa. This research was complete at my homestay in 
Bursins, Switzerland.  
21/10/14         Duration: 5:00 
After reviewing the presentation given to our program at the WHO about UNITAIDS by Mrs. 
Gelise McCullough, I became interested in pediatric HIV. I was so inspired that I changed the 
topic of my ISP to HIV drug resistance among infants and children in South Africa. I was 
curious as to some of the determining factors of HIV drug resistance and how this problem is 
being addressed among pediatric populations. I then researched secondary sources for 
publications and studies on this topic through journal databases such as PLoS ONE (the Public 
Library of Science), PubMed.gov, and Web of Science. This was carried out at the UNOG 
Library, Palais des Nations 1211 Geneva.  
22/10/14-27/10/14        Duration: 32:00 
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During this week, I did a lot of research on my topic at various locations including my homestay 
in Bursins, the UNOG Library at the Palais des Nations, the SIT office in Nyon, and the 
Starbucks by the Geneva train station. It was a little overwhelming at times, because I was 
finding a lot of information on HIV infection among children and drug resistance. There was a 
lot to sort through and some of the dialogue was challenging due to its scientific nature. 
Throughout this period, I contacted several potential interviewees. On 23/10 I emailed Dr. 
Martina Penazzato and Mr. Martin Auton from the ARV Procurement Working Group and the 
World Health Organization. Then on 25/10 I emailed more potential interviewees including Dr. 
Marc Lallement and Dr. Brian Eley, members of Technical Reference Group on Pediatric HIV 
Care and Treatment: South Africa. I emailed Mrs. Dorine Da re-van der Wal from the WHO to 
refer me to Gelise McCullough since I did not have her email from the presentation. Finally, I 
emailed Dudley Tarlton, who gave our program a presentation on the UNDP’s partnership with 
the Global Fund and their efforts to end HIV/AIDS.  
28/10/14          Duration: 5:30 
Today, I secured my first formal interview with Gelise McCullough, Technical Director for 
UNITAIDS. We scheduled the interview for Thursday October 30, 2014 at 10:00 at the WHO 
building in Geneva. I was considering asking her to be my advisor after the interview. I 
continued writing my paper too. 
29/10/14         Duration: 6:30 
While at the Starbucks in Geneva, I continued my research. I also started writing my paper 
today. I completed the first draft of my introduction.  
30/10/14         Duration: 2:00 
Today, I had my formal interview with Gelise McCullough at the World Health Organization. 
Avenue Appia 20 1211 Geneva 27 Switzerland. We sat in the café, drank coffee, and talked 
about pediatric HIV and the work of UNITAIDS in the WHO cafe. All of my prepared questions 
were answered and then we spent twenty minutes just discussing more about pediatric HIV in 
general such as TB co-infection and PMTCT efforts. Hand notes were taken throughout the 
interview. I learned about her side work where she paints her experiences and uses the profits to 
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fund children’s education. At the end of the interview, Mrs. McCullough agreed to be my advisor 
and gave me several contacts for more interviews. The two contacts were Dr. Badara Samb with 
UNAIDS and Francesca Celletti with EGPAF. Afterwards, I reflected on the interview and typed 
up my transcript. She also told me that the money she would get from being my advisor would 
be sent to a child in Kenya to fund his/her education which is really exciting! 
05/11/14         Duration: 7:00 
I continued writing my paper and completed the first draft of chapters titled: Pediatric HIV in 
South Africa, Pediatric HIV Drug Resistance, Challenges to Pediatric HIV Care, and 
Opportunities for Pediatric HIV Care. This writing occurred in SIT office in Nyon, Switzerland 
and at the Starbucks in Geneva. I was having trouble finding other interviews since none of the 
experts I emailed responded. 
06/11/14         Duration: 6:00 
While writing my paper, I received a response from Dr. Samb saying that he was traveling for 
the remainder of the year but he referred me to Dr. Reuben Granich, a Senior Advisor of Care 
and Treatment for UNAIDS. I sent an email to Dr. Granich explaining my research and 
requesting an interview. He responded within several minutes and I set up my second formal 
interview for the following day at 10:00 at the UNAIDS building. I then continued drafting my 
paper with the chapter on the WHO Pediatric ART Guidelines and prepared the questions for my 
interview the next day.  
07/11/14         Duration: 3:00 
My second formal interview was today with Dr. Granich at the UNAIDS building Avenue Appia 
20 1211 Geneva 27 Switzerland. Luckily it was across the street from the WHO main building, 
so I had no trouble finding this location. Questions were prepared but conversation deviated from 
those topics slightly. I found two WHO technical reports, “Access to Antiretroviral Drugs in 
Low-and-Middle-Income Countries July 2014” and “Technical and Operational Considerations 
for Implementing HIV Viral Load Testing July 2014” that I was allowed to take with me for 
further research. Additionally, I asked if there were any conferences or public events. Dr. 
Granich said he would invite me to any meetings if there were any in the near future. I returned 
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to my homestay to type the transcript. Here, after asking about my interview, my host mom told 
me that our old neighbor, Paula Hacopian (who moved a week after I arrived in Switzerland) 
worked with the subject of HIV/AIDS. She said she would call and ask if she was available to 
meet with me.  
08/11/14-09/11/14        Duration: 14:00 
These days were spent writing my paper at the SIT office in Nyon. I worked on the chapters of 
the South African National Guidelines, NGO Strategies, and the WHO and South African 
Response to HIVDR. I could not find the phone numbers for the experts who did not respond, so 
I sent a second email asking if my first had reached their inbox.  
10/11/14         Duration: 6:00 
My host mom gave me Paula’s number and said that I could call to schedule a meeting. After 
several tries, I left a message. Paula called me back while I was working on my paper in the SIT 
office. She said that she worked with the Global Fund and would contact a colleague who was 
more knowledgeable in the field of pediatric HIV.  
11/11/14         Duration: 6:30 
I got a response today from Dudley Tarlton, and we set up a formal interview for the upcoming 
Thursday at 11:00 at the UNDP. I also got an email from Dr. Lisa Nelson, the colleague of Paula 
Hacopian. Even though she was working in South Africa, she said she would be back in 
Switzerland the following week. We scheduled the meeting for the upcoming Monday, 
November 17, 2014. The rest of my time was spent preparing the questions for my interview on 
Thursday and writing the paper.  
13/11/14         Duration: 2:00 
My third formal interview was today at 11:00 at the UNDP located at 11-13 Chemin des 
Anémones, 1219 Châtelaine, Geneva with Dudley Tarlton. His colleague, Fabien Lefrancois also 
joined for the interview. I learned that the UNDP does not deal directly with the Global Fund 
grants in South Africa but both interviewees provided a lot of helpful information on 
procurement of grants and how the UNDP works to develop capacity.  
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16/11/14         Duration: 4:00 
On my train ride back from Milan, I typed up my notes from my interview on Thursday and 
added some of that information to my paper. Once I returned home, I edited my paper and 
prepared the questions for my interview on Monday.  
17/11/14         Duration: 5:00 
I had my final formal interview today with Dr. Lisa Nelson, a Senior HIV Disease Advisor with 
the Global Fund. Our interview lasted for 45 minutes and was held in the café of the Global Fund 
building located at Chemin de Blandonnet 8 1214 Vernier-Geneva, Switzerland. She had just 
been travelling in South Africa and I learned a lot about the global fund grants in this area. After 
the interview, I returned to my homestay and typed up the transcript. I then finished the first draft 
of my paper which I emailed to my advisor to edit.  
18/11/14         Duration: 7:00 
In the morning at my homestay, I edited my paper again and completed the interactive research 
log. I also started my presentation which I will give on Thursday. I decided to use Powerpoint 
during the presentation. I then went the SIT office in Nyon where I continued my work.  
19/11/14         Duration: 6:30 
After the first day of presentations, I finalized my presentation. My advisor sent her edits back to 
me today so I was able to make a final revision of my paper. I submitted the final copy to the 
program director and academic advisor along with my powerpoint presentation.  
Interview Transcripts 
Interview 1  
Interviewee: Gelise McCullough (GM): Technical Director UNITAIDS 
Location: World Health Organization Avenue Appia 20 1211 Geneva 27 Switzerland 
Date & Time: 30/10/14 at 10:00-11:00 
Q: What is your job? 
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GM: I have worked with UNITAIDS for 6 years. I work on strategy and am a civil society focal 
point. So I work with those infected a lot. I do a lot of in-country consultations where I meet with 
those infected, care-givers, and the government to make sure they are working together to 
strengthen the health care system. I mainly go to medical facilities like hospitals where you can 
really see the strength of health systems and what is lacking. I have been to many places 
including Senegal, Liberia, Mali, Kenya, Tanzania, and Myanmar.  
Q: Why do children have difficulty adhering to their ARV therapies? 
GM: ARV has to be easy and children’s ARVs are not. There are weight bands to consider and 
medicines are hard to take. There are also big difficulties in the market. Currently, LPV/r for 
infants is only in syrup form which is bad-tasting. So there are three big reasons why children 
have trouble adhering: 1) it is difficult to take 2) There are social factors involved. Women will 
know their positive status but their husbands don’t so revealing the child’s status causes huge 
problems. As an example, a Kabira woman living in a hostel hid her child’s medication and 
didn’t give them religiously. Her child is now on 2nd line treatment. 3) A lack of good 
diagnostics. When patients are monitored better by health officials, they do better on their 
treatments.  
Q: How close is UNITAIDS in bridging the treatment gap among children? 
GM: The good thing about pediatric HIV is that we are not alone. There are many actors 
working together including PEPFAR, UNAIDS with the political lobby, UNITAD, and the 
Global Fund. We (UNITAIDS) have the diagnostics but PEPFAR will scale it up because they 
have a lot more funding. Our public health impact is a combined effort. The treatments are there 
but we’re not finding the children in need. We have been investing in early infant diagnosis 
which is needed because diagnostic tests are different for children than for adults. (You can’t test 
infants like adults because the mother’s HIV virus could be detected instead of the child’s). Now 
there is a push to testing kids as soon as possible, at around 12 weeks. The problem is getting 
mothers back in for results. Currently only 50% of mothers come back for results. So we need to 
find the kids, get them diagnosed, get the results, get the kids on treatment, and have better 
formulations.  
Q: How does UNITAID work with other organizations? 
GM: The interests and desires of UNITAID, PEPFAR, CHAI and others have to match which is 
difficult at times. UNITAIDS doesn’t work directly with pharmaceutical companies, because we 
have to keep neutrality in mind so there is no conflict of interests. But we (UNITAIDS) give 
money to CHAI who gives money to pharmaceuticals.  
Q: Do you think drug resistance testing (genotypic testing) before switching treatments is cost-
effective? (For instance, to determine if viral load is actually high enough to fail 1st line?)  
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GM: Not at the moment. It is not viable right now because it costs $300 per test. Sister Mary 
believes that now, when viral load increases (detected in a test) and there’s a switch to second 
line treatment, this is a blind approach. It is like switching form one blind therapy to another. 
You don’t know what resistant mutations there are or if the real problem is with resistance or 
adherence. Another huge issue is that kids suffer very quickly from drug resistance. Maybe we 
(UNITAIDS) could work with Sister Mary and her cohort of children. What could we learn if we 
paid for 3,000 or so children to get genotype therapy?  
Viral load testing is a blood test: how much virus is in the blood? If the virus is undetectable, the 
medication is working. When the virus is detected, the therapy is either failing or the patient is 
not taking his/her medications. You can count the number of drugs (pills) too but you can flush 
them down the toilet. We are now doing a urine test to see if patients are taking their drugs 
because people lie.  
Q: Are there any viable third-line therapies for children? 
GM: Not exactly. It’s still very much in the clinical stage. Sister Mary in Kenya gets them from 
compassionate donations (she goes around and asks for treatments). They are so expensive 
costing around $3,500 per year. People try using adult medication by splitting tablets but the pills 
are not made evenly. So giving a child half of a pill doesn’t mean that you are giving them half 
the dose. These treatments are not adapted well to children. One child on third line must take 9 
pills in the morning and 9 at night. In Sister Mary’s cohort, kids have a lot of inherited 
resistance. Those she treated early on in her program were just given whatever was available and 
we are now seeing a lot of drug resistance. 
Q: How can we reduce drug resistance among children? 
GM: - Get testing done quickly and correctly at the start 
- Help the mother get to care facilities so she can give the ART to her kids 
- Simplifying medications makes it easier to treat kids. How easy would it be to only need to 
give one pill in the morning? 
In the Kenyan orphanage, children would discriminate each other based on how many pills the 
other would have to take. All the kids have HIV and all are on ART but they are on different 
programs. One might discriminate another saying “oh he has 4 pills, he’s sicker than me”.  
Q: I was reading that UNITAIDS is only active with one program in South Africa, the 
“Implementation of CD4 and viral load testing in decentralized, remote and resource-limited 
settings in MSF HIV programs”. Are there any other programs in South Africa? 
GM: South Africa is pretty self-sufficient. None of our projects directly go to South Africa but a 
lot of our work benefit that country.  
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---------------------------------------End of prepared questions---------------------------------------------- 
Q: What about the WHO Guidelines for Treatment? 
GM: They are very important. The biggest change was the CD4 count from 500 to 350. Not 
many countries can manage this switch yet (viral load testing is not readily available). Countries 
want to switch but don’t have the capacity to treat all of those patients. A simplification with 
Point of Care diagnostics will help. It’s not often doctors that are doing the diagnostic work so 
there needs to be more training. 
Q: And the WHO recommendations…? 
GM: Breast feeding exclusively. Moms get conflicted because they know they could transmit to 
their kids if they breastfeed so they switch sometimes to bottle which is worse because it 
damages the gastro-intestinal tract. Kids are tested at 12 and 18 months to see if viral load is 
different and see if feeding has given the child HIV.  
Q: How efficient is PMTCT? 
GM: Birth is always a dangerous affair. There’s always a chance of transmission with blood 
contact between the infant and mom. It often depends on the circumstance whether the kid will 
be infected. It all depends on how quickly you diagnose the pregnant mom, whether she 
continues treatment after birth, and how quickly you test the infant after birth. Pregnancy takes a 
huge toll on the body: energy levels are down and the mother’s immunity goes down. When they 
get sick, they have a higher viral load which means a higher chance of transmitting the HIVV to 
the child.  
The sad reality is that a lot of kids die in Africa. With a mother who loses a child, maybe it is her 
HIV positive child that dies and she thinks “I’ll have another and maybe it will be okay”. There 
is a lot of stigma and discrimination around HIV treatment and diagnosis. For example, it is 
better if the child is severely malnourished than malnourished. The severely malnourished child 
will stay in a hospital and get good care while the malnourished child gets extra food and 
nutrients which the mom gives to all of the children in the family and not just the HIV positive 
one. The stigma factor is a huge reason why mothers don’t get their kids tested. 
Q: How does treatment as prevention work? 
GM: In discordant relationships, one partner has HIV and the other doesn’t. The idea is that if 
you can get viral suppression down in a group of people, transmission should be reduced. But in 
Africa, men have multiple partners at a time and have multiple wives. Some wives think they are 
lucky to have husbands and can’t control the sexual actions of their husbands (like ask him to 
wear a condom etc). So he can go and have sex with others and bring HIV back to his wife. In 
some relationships, when 1 wife is HIV +, the others want it because that means they are having 
sex with their husband. Also other STIs are conductors of HIV.  
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Q: Are there complications with ART? 
GM: Another reason why children develop resistance to HIV drugs is due to toxicity and loss to 
follow up. Adults can have 50 years on HIV treatment but with children, we don’t know how 
long. When you grow up with HIV and on ART, how much effect does the virus have on the 
child as he grows? Sister Mary notices that there are heart problems with her adult patients that 
started treatment as kids. 
There is terrible adherence with teenagers and specifically boys born with HIV. At 12 years old, 
mothers disclose care to their kids and let them in charge of their medication. There is also a 
huge problem with adolescent girls being infected. Lots of work is needed to address this issue 
such as campaigns to keep them in school and to change laws on child marriage.  
Q: Can you talk about the PMTCT efforts? 
GM: With PMTCT, we hope to eliminate transmission but there will always be a trickle of kids 
getting infected. We will never get it down to zero. Now with the B+ option, early antenatal tests 
that are positive will immediately be put on ARVs (if the mother even goes to antenatal clinic). 
When viral loads are lower, transmission is lower. We are now working with doctors in Liberia 
so they can treat HIV themselves rather than referring patients to other doctors.  
Q: How does co-infection with TB and HIV affect people? 
GM: 1/3 of the population is infected with TB but not all show it and develop it. The TB 
epidemic is at its peak in Africa. Here, it shows up and develops in this population more than in 
higher-income countries, because they don’t have good sanitation or a stable health care 
infrastructure. There is a ½ chance of developing TB in people with HIV because they have a 
suppressed immunity system. TB thrives in these settings and the first killer of people with HIV 
is TB.  
With those who are TB diagnosed, the 1st line treatment is an intensive 2 months (which makes 
patients feel a lot better) then a continuation for 4 months. However, if the patient defaults in 4 
months, there is a nasty multi-drug resistance. There are not good TB drugs on the market as 
well. More and more, we are finding HIV infected kids by them testing positive for TB. Pediatric 
TB is a huge problem in Africa. How do we find these children? ½ of them will die before 2 but 
we are not doing anything to find the other half that live. A solution could be implementing 
vaccine programs through schools. Example: Juliana wasn’t diagnosed HIV positive and started 
on ART until she was 10 years old! 
Interview 2 
Interviewee: Dr. Reuben Granich (RG) : Senior Advisor, Care and Treatment 
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Location: Joint United Nations Program on HIV/AIDS (UNAIDS) Avenue Appia 20 1211, 
Geneva 27 
Date & Time: 07/11/14 at 10:00-11:00 
Q: What is your job? 
RG: I am an epidemiologist by training but I work as a tactician now. I am from the CDC and 
have been secunded here. In 2009, my small group published an article in Lancelet. In the article, 
we argued that if we tested and treated everyone in South Africa, we could eliminate HIV. This 
was a modelling paper and ruptured the way people thought about treatment. Now, partly due to 
this paper and others, treatment is not only seen as clinical but as a preventative measure. Your 
lifespan is near normal when you are put on treatment. Before there are two camps, the testing 
camp and the treatment camp—they usually worked in separate work streams. Everyone agrees 
that it is important to get tested in order to know your status. In our paper, we combined the two 
streams by exploring what would happen if everyone is tested and those who test positive would 
be put on treatment immediately.  
UNAIDS is a multilateral agency working on the global drive of the HIV response. They provide 
leadership and manage resources. 
Q: What are the limitations for pediatric HIV treatment in South Africa?  
RG: I am not a pediatric ART expert, but I can see two main limitations. 1) Drug formulations 
aren’t as refined for kids as they are for adults due to issues such as weight bands. 2) There are 
delivery problems and perhaps the pediatric treatment guidelines make it too complex of a 
system for treating kids. Just compare the guidelines for children and for adults; the pediatric 
guidelines are probably more complex. There are also fewer studies involving children and the 
main advocates for children are their parents.  
Pediatric HIV treatment is also somewhat of a downstream approach. We must remember to also 
focus on upstream interventions. If mothers never got infected, she would never transmit to her 
kids. It is important to focus on treatment of adults and kids. Option B+ is more of an upstream 
approach by encouraging all mothers to be on treatment. It was hugely controversial at first. 
Malawi led the charge, and their initiative was widely successful from the start. Allowing access 
to treatment for pregnant mothers is a three-for. It keeps the mother healthy, and prevents 
transmission to their babies and their partners. 
Q: Why do children have difficulty adhering to ARTs? 
RG: Getting kids to take their medication is difficult. Formulations taste bad and there are a lot 
to take. Poverty is also a huge issue. Scheduling monthly appointments at the clinic is really 
difficult for the mothers to do. Often, clinics aren’t open long enough and there are longs lines as 
mothers and children wait for appointments. We must work on designing a system that can reach 
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everyone. In South Africa, you can’t do it all in the clinics. There aren’t enough resources for 
everyone in need to get treatment at the same place every month. There are sociocultural issues 
to deal with too such as disclosure problems and the stigma and discrimination around a positive 
diagnosis. 
Q: I was looking through the presentations on your dropbox and saw a graph showing that in 
South Africa, pediatric ART coverage was around 48% while for adults it was around 40%. Why 
is pediatric coverage higher than adult? 
RG: Not sure without looking at the figures, but you also have to be careful of what is actually 
being calculated. The way coverage is calculated changes when the WHO changes policies 
regarding treatment. For example, in the past WHO eligibility for treatment was a CD4 count of 
<200. Now that it is a CD4 count <500, the denominator of who is eligible changes. The real 
picture is that 35 million people living with HIV will need treatment to remain healthy—without 
treatment or they will die in 10 years. We have over 13 million on treatment but the remaining 
people who are not on treatment have about a 10 year lifespan if they do not get treatment. In 
other words, whether more kids or adults are getting treatment, there is still a large treatment gap 
for both adults and children. Also there is a cascade. Of all the people with HIV, how many of 
those know their status? Of those, how many are on ART? And of those, how many have viral 
suppression? So in the end, what percentage is actually on treatment matters but what is most 
important is the number of people who are on successful treatment for the long term. 
Q: Is drug resistance testing such as genotypic testing an effective tool when deciding to switch 
from first-line to second-line treatment? 
RG: The problem is that this sort of testing is not available to a majority of the world. The tests 
that are mainly used is the HIV antibody test which shows whether you have been exposed and 
infected and the CD4 test which is a crude measure of the immune system. Genotype testing is 
an expensive approach available in wealthier countries and research laboratories but a good one, 
because when you know resistance patterns, you can tailor responses and treatments. There are 
ethical considerations too. Do you provide genotype testing for kids or make sure everyone has 
access to basic HIV and CD4 cell testing? Also, you have to look at what regimens you have. If 
you only have one first line and one second line option, doing genotype testing may not help 
since you have limited options to tailor the treatment regimen. 
Q: South Africa’s national policies for pediatric HIV treatment are concurrent with the 2013 
WHO Guidelines to commence ART irrespective of CD4 count. How will this improve ART 
coverage for more children? 
RG: The previous policies often translated into “test and wait”. Of course some children were 
eligible but others were told to wait until they had further immune degradation. If you ask people 
to wait then they may die or they could come back really sick, get on ART, and then die. People 
from the community then may say “oh look, ART kills people.” It is probably a much better 
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system now to start the kids right away on treatment. This new policies will expand the number 
of children able to get treatment and provide support for them to adhere to their therapies. It will 
also keep the children healthier as well. 
Q: How closely to written policies reflect program implementation or clinical practice? 
RG: Although some countries have already adapted their policy to the new science, others adapt 
soon after WHO makes the change. Other countries wait for a while. To develop WHO policies 
ia a 2-3 year process. It takes 2 years to develop the policies and then can take longer for some 
countries to adapt to them. You also can’t assume that program implementation accurately 
reflects the policy. When there are changes, governments make shifts and drive new responses 
within the health system. But this can be a long time period for someone with HIV. 
Q: What is the collaboration among UNAIDS and other organizations such as UNITAIDS, the 
Global Fund, PEPFAR, and CHAI? 
RG: It is a complex web of relationships. UNAIDS provides global leadership but also gets 
funding from PEPFAR so this is a deep collaboration. . There is also a collaborative effort on 
testing with UNITAID and around monitoring and modeling with CHAI. UNAIDS also works 
closely with the Global Fund on efforts to fund the response. You could write books about the 
relationship. 
Q: What are the ethical considerations when dealing with HIV treatment among children? 
RG: There are many. The main ethical issue usually revolves around the fact that in most places 
children are less likely to get treatment than adults. Given that children rely on adults for 
protection and treatment this is ethically wrong. The other ethical dilemma has to do with 
resources. We have the resources to treat everyone, adults and children, to not do so raises 
ethical issues. We also spend resources on trials and studies, some for children. These are 
important but raise ethical issues—should some of these resources go towards treating children. 
These are just some of the issues we are struggling with in our response. 
Interview 3 
Interviewees: Dudley Tarlton (DT): Program Specialist, Health and Development UNDP &  
Fabien Lefrancois (FL): Policy Specialist, Partnership with the Global Fund UNDP 
Location: 11-13 Chemin des Anémones, 1219 Châtelaine, Geneva, Switzerland 
Date & Time: 13/11/14 at 11:00-11:45 
Q: How does the UNDP operate within a country? 
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FL: We have a partnership with the Global Fund (GF). In countries, we set up a co-PR modality. 
We act as the interim recipient of the GF grant until the country is capable of managing the 
funds. Procurement is not easily transferred, but it is a gradual process. You have to meet 
milestones within a capacity development plan. You also need the resources to develop and 
implement the grants. Then there is the policy environment where we promote an enabling 
environment by working with the government. For instance, we assess barriers to access of 
health (such as men who have sex with men in countries where this is illegal). The eligibility for 
GP funding depends on income and disease burden. With a higher income, the more focused you 
have to be on how you spend GF money. Yet the income of the country doesn’t necessarily paint 
the picture for everyone there.  
DT: UNDP doesn’t deal with the GF grants in South Africa but at a conference I was just at, 
there was a video playing of the South African minister of health. He said that after looking 
around and seeing that South Africa was paying more for HIV drugs than neighboring countries, 
they negotiated price reductions for ARVs.  
Q: How does the UNDP develop capacity in countries where it is acting as the interim grant 
recipient? 
DT & FL: We build capacity, then hand it over. We look at different functions to implement GF 
grants and the status of those functions. Some of the functions are financial, risk management, 
and MNE. We work with national partners, ministers of health etc. We are the principal 
recipients of the GF grants but are not in charge of their entire implementation (work with 
program management embedded in Ministries of Health). 
Q: This is country-dependent but do you think the grants are used more for testing or for 
treatment?  
DT & FL: I would imagine more is spent on treatment. With testing, it’s not the amount of it but 
who you test. A country can say they test a million people, but are they reaching the right 
populations? So we have to target risk populations. There is a limited amount of money and it is 
hard to scale up response when [WHO] guidelines change. The treatments must be sustainable 
and now, testing and treatment are sort of being lumped together with the idea of treatment as 
prevention.  
Q: Does UNDP have a role in the HIV drug market? 




Interviewee: Lisa Nelson, MD (LN): Senior HIV Disease Advisor 
Location: The Global Fund Chemin de Blandonnet 8 1214 Vernier-Geneva, Switzerland 
Date & Time: 17/11/14 at 14:00-14:45  
Q: What is a brief description of your job? 
LN: I am a Senior HIV Disease Advisor. Part of my work is internal where we provide guidance 
to the operation of the Global Fund (GF) grants and part of it is external where we work with 
partners such as the WHO and UNICEF.  
Q: I was looking at the website and saw there are 9 active Global Fund grants in South Africa 
that deal with HIV/AIDS. Where does the money come from and how is it used? 
LN: The GF was started in 2002 by Kofi Annan, former Secretary-General of the United 
Nations. He saw a major gap in the funding. The GF is a multilateral agency with donors around 
the world. The biggest donor countries are the United States and France. It started as a 
performance based fund where countries has to compete for money but there is a new funding 
model now where we look at the ability of a country to pay and their need. Also money is set 
aside for each country until that country can submit a good application for a grant.  
Q: Do any of these grants deal with pediatric HIV? 
LN: The GF set up Country Coordinating Mechanisms (CCM) at country level. We recognize 
that ministers of health and governments themselves are important in implementing the grants, 
but we also want the targeted populations to have a role in implementation. The CCM proposes 
what to do with the money, decides when to apply the grants, and decides who the principle 
recipients of care are. 60% of the funds go to commodities (ARVs are so expensive).  
Q: Is more grant money spent on testing or treatment?  
LN: Treatment. The cheapest 1st line, for adults not kids, is still over $100 per patient per year. 
That doesn’t seem like a lot but when you have thousands on treatment, it becomes millions of 
dollars which is the bulk of the grant.  
Q: How is the performance of a grant calculated? (How does one meet expectations?) 
LN: When a country writes a grant, they include assessment models in their proposals. The new 
funding model is that grants are 3 years long so countries are now applying for 2015, 2016 and 
2017. There are regular check ins and progress reports. Performance is also monitored against 
country targets set in the proposal.  
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Q: How is access to ART increasing in South Africa? 
LN: There has been a complete transformation in the way South Africa is dealing with HIV since 
2009 when Jacob Zuma became President. The government is now doing more to broaden HIV 
drug access to pregnant women and infants and to start ART sooner. Most of the treatment is 
now funded by the government itself.  
Q: Can you tell me about HIV drug resistance surveillance in South Africa? 
LN: In the USA, if a person tests positive for HIV, you would check drug resistance to tailor a 
treatment. But many countries lack the resources to provide this. South Africa is somewhere in 
the middle, because it has higher lab capacity than neighboring countries and it might even have 
private clinics. The WHO has recommendations to do periodic drug resistance surveys with 
representative populations.  
Q: Is HIV drug resistance (genotypic) testing cost-effective? If not, can it be in the future? 
LN: At the moment, it is not feasible to do for each patient. The drug supply chain is fragile and 
so are health care systems. Everyone gets the standard first line treatment. But even if genotypic 
testing was cost effective, it would be hard to operationalize all these systems and changes. One 
hopes there will be a dip stick test (a low cost strategy) for drug resistant HIV to identify 
mutations. There has been success with TB. The gene expert test detects TB and Rifampicin (the 
main drug used) resistance. It isn’t exactly point of care because it uses electricity but it could be 
used in the rural setting to test right there. Of course it is still relatively expensive and not 
available everywhere but with this, a patient can come in, get tested, and be put on a treatment 
that they will respond well to.   
Q: How can we reduce HIV drug resistance among infants and children? 
LN: You start with the general population. We know poor adherence is a major factor. There 
needs to be better treatment options. Right now, formulations for children are hard to take, are in 
liquid form, and must be taken multiple times per day. Since the PMTCT strategies have 
increased, more people are on ART so naturally drug resistance will increase. Also before 
recently, single-dose nevirapine was used and using one drug is a good way to get drug 
resistance. Now we are going to combination formulations for PMTCT. Before, drugs were less 
potent and we would say we needed 95% adherence which is really difficult. With drugs being 
more potent now, they are more forgiving in regards to resistance and we can have a lower 
percent of adherence. There is also viral load monitoring. WHO recommends monitoring to 
identify failure quickly. If failure is not found quickly, it will amplify the resistance.  
Q: Do you think increasing media efforts and education on HIV would improve adherence for 
children? 
LN: I don’t know if mass media efforts will do that much because people think that it doesn’t 
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apply to them. We do know that peer support is very important and so is working with 
communities. With children, it is harder to hide that they are on ART and harder to hide their 
status which is a reason why mothers don’t get their children tested.  
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Interview at the WHO café. 
Questions prepared ahead of 
time were answered, and 
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Interview at the UNAIDS 
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treatment as prevention and 
I learned of his modeling 
study conducted in 2009. I 
got two reports written by 
the WHO on HIV drug 
resistance and HIV 
medication in low-middle 





















Interview at the UNDP 
cafeteria. We discussed the 
role of the UNDP and how 
their partnership with the 





























I called Paula to arrange a 
meeting with one of her 
colleagues. She directed me 
to Dr. Lisa Nelson.  
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